Articles

Milk Thistle

On oktober 22, 2021 by admin

Albrecht M, Frerick H, Kuhn U, and et al. Die Therapie toxischer Leberschaden mit Legalon. Z Klin Med 1992;47(2):87-92.

Allain, H., Schuck, S., Lebreton, S., Strenge-Hesse, A., Braun, W., Gandon, J. M., and Brissot, P. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer’s disease. Dement.Geriatr.Cogn Disord. 1999;10(3):181-185. Bekijk abstract.

Angulo, P., Patel, T., Jorgensen, R. A., Therneau, T. M., and Lindor, K. D. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;32(5):897-900. Bekijk abstract.

Anon. Adverse reaction: milk thistle-associated toxicity. Nurse Drug Alert 1999;23(7):51.

Asghar, Z. and Masood, Z. Evaluation of antioxidant properties of silymarin and its potential to inhibit peroxyl radicals in vitro. Pak.J Pharm Sci 2008;21(3):249-254. View abstract.

Barzaghi, N., Crema, F., Gatti, G., Pifferi, G., and Perucca, E. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 1990;15(4):333-338. View abstract.

Basaga, H., Poli, G., Tekkaya, C., and Aras, I. Free radical scavenging and antioxidative properties of ‘silibin’ complexes on microsomal lipid peroxidation. Cell Biochem Funct. 1997;15(1):27-33. Bekijk abstract.

Batakov, E. A. . Eksp.Klin Farmakol. 2001;64(4):53-55. Bekijk abstract.

Bean, P. Het gebruik van alternatieve geneeswijzen bij de behandeling van hepatitis C. Am.Clin.Lab 2002;21(4):19-21. View abstract.

Becker-Schiebe, M., Mengs, U., Schaefer, M., Bulitta, M., and Hoffmann, W. Plaatselijk gebruik van een preparaat op basis van silymarine ter preventie van radiodermatitis : resultaten van een prospectieve studie bij borstkankerpatiënten. Strahlenther.Onkol. 2011;187(8):485-491. Bekijk abstract.

Benda, L., Dittrich, H., Ferenzi, P., Frank, H., and Wewalka, F. . Wien.Klin.Wochenschr. 10-10-1980;92(19):678-683. View abstract.

Bhatia, N. and Agarwal, R. Nadelig effect van kankerpreventieve fytochemicaliën silymarine, genisteïne en epigallocatechine 3-gallate op epigenetische gebeurtenissen in humaan prostaatcarcinoom DU145 cellen. Prostate 2-1-2001;46(2):98-107. Bekijk abstract.

Boari, C., Montanari, F. M., Galletti, G. P., Rizzoli, D., Baldi, E., Caudarella, R., and Gennari, P. . Minerva Med 10-20-1981;72(40):2679-2688. Bekijk abstract.

Bode, J. C., Schmidt, U., and Durr, H. K. . Med Klin. 3-25-1977;72(12):513-518. View abstract.

Bokemeyer, C., Fels, L. M., Dunn, T., Voigt, W., Gaedeke, J., Schmoll, H. J., Stolte, H., and Lentzen, H. Silibinin protect against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumor activity. Br J Cancer 1996;74(12):2036-2041. View abstract.

Brinda, B. J., Zhu, H. J., and Markowitz, J. S. A sensitive LC-MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma. J.Chromatogr.B Analyt.Technol.Biomed.Life Sci. 8-1-2012;902:1-9. Bekijk abstract.

Carducci, R., Armellino, M. F., Volpe, C., Basile, G., Caso, N., Apicella, A., and Basile, V. . Minerva Anestesiol. 1996;62(5):187-193. View abstract.

Carini, R., Comoglio, A., Albano, E., and Poli, G. Lipide peroxidation and irreversible damage in the rat hepatocyte model. Bescherming door het silybine-fosfolipidecomplex IdB 1016. Biochem Pharmacol 5-28-1992;43(10):2111-2115. View abstract.

Cavalieri S. A controlled clinical trial of Legalon in 40 patients. Gazz Med Ital 1974;133:628-635.

Comoglio, A., Tomasi, A., Malandrino, S., Poli, G., and Albano, E. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Biochem.Pharmacol 10-12-1995;50(8):1313-1316. View abstract.

de Font-Reaulx, Rojas E. and Dorazco-Barragan, G. . Rev.Neurol. 5-1-2010;50(9):520-528. Bekijk abstract.

De Martiis, M., Fontana, M., Assogna, G., D’Ottavi, R., and D’Ottavi, O. . Clin Ter. 8-15-1980;94(3):283-315. View abstract.

Dehmlow, C., Murawski, N., and de Groot, H. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 1996;58(18):1591-1600. View abstract.

Desplaces, A., Choppin, J., Vogel, G., and Trost, W. The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung. 1975;25(1):89-96. View abstract.

Detaille, D., Sanchez, C., Sanz, N., Lopez-Novoa, J. M., Leverve, X., and El Mir, M. Y. Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci 5-23-2008;82(21-22):1070-1076. Bekijk abstract.

El-Kamary, S. S., Shardell, M. D., Abdel-Hamid, M., Ismail, S., El-Ateek, M., Metwally, M., Mikhail, N., Hashem, M., Mousa, A., Aboul-Fotouh, A., El-Kassas, M., Esmat, G., and Strickland, G. T. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Fytomedicine. 2009;16(5):391-400. View abstract.

Eurich, D., Bahra, M., Berg, T., Boas-Knoop, S., Biermer, M., Neuhaus, R., Neuhaus, P., and Neumann, U. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp.Clin.Transplant. 2011;9(1):1-6. Bekijk abstract.

Fallah Huseini, H., Larijani, B., Fakhrzadeh, H., Rajabi Pour, B., Akhondzadeh, S., Toliat, T., and Heshmat, R. De klinische proef van Silybum Marianum zaad extract (Silymarin) op type II diabetische patiënten met hyperlipidemie. Iran J.Diabetes Lipid Disord. 2004;3(2):201-206.

Fallahzadeh, M. K., Dormanesh, B., Sagheb, M. M., Roozbeh, J., Vessal, G., Pakfetrat, M., Daneshbod, Y., Kamali-Sarvestani, E., and Lankarani, K. B. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with open nephropathy: a randomized, double-blind, placebo-controlled trial. Am.J.Kidney Dis. 2012;60(6):896-903. View abstract.

Feher, J., Lang, I., Nekam, K., Muzes, G., and Deak, G. Effect van vrije radicaalvangers op het superoxide dismutase (SOD) enzym bij patiënten met alcoholische cirrose. Acta Med Hung. 1988;45(3-4):265-276. View abstract.

Fintelmann V. Zur Therapie der Fettleber mit Silymarin. Therapiewoche 1970;20:1055-2064.

Flaig, T. W., Glode, M., Gustafson, D., van, Bokhoven A., Tao, Y., Wilson, S., Su, L. J., Li, Y., Harrison, G., Agarwal, R., Crawford, E. D., Lucia, M. S., and Pollak, M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 6-1-2010;70(8):848-855. View abstract.

Flory, P. J., Krug, G., Lorenz, D., and Mennicke, W. H. . Planta Med 1980;38(3):227-237. View abstract.

Frerick F, Kuhn U, and Strenge-Hesse A. Silymarin–ein Phytopharmakon zur Behandlung toxischen Leberschaden: Anwendungsbeobachtung bei 2169 Patienten. Kassenarzt 1990;33:36-41.

Fried, M. W., Navarro, V. J., Afdhal, N., Belle, S. H., Wahed, A. S., Hawke, R. L., Doo, E., Meyers, C. M., and Reddy, K. R. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccesfully treated with interferon therapy: a randomized controlled trial. JAMA 7-18-2012;308(3):274-282. Bekijk abstract.

Gaedeke, J., Fels, L. M., Bokemeyer, C., Mengs, U., Stolte, H., and Lentzen, H. Cisplatin nephrotoxicity and protection by silibinin. Nephrol.Dial.Transplant. 1996;11(1):55-62. View abstract.

Gatti, G. and Perucca, E. Plasmaconcentraties van vrij en geconjugeerd silybine na orale inname van een silybine-fosfatidylcholine complex (silipide) bij gezonde vrijwilligers. Int.J Clin Pharmacol.Ther. 1994;32(11):614-617. View abstract.

Gharagozloo, M., Moayedi, B., Zakerinia, M., Hamidi, M., Karimi, M., Maracy, M., and Amirghofran, Z. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fundam.Clin.Pharmacol. 2009;23(3):359-365. View abstract.

Giorgi, V. S., Peracoli, M. T., Peracoli, J. C., Witkin, S. S., and Bannwart-Castro, C. F. Silibinin modulates the NF-kappab pathway and pro-inflammatory cytokine production by mononuclear cells from preeclamptic women. J.Reprod.Immunol. 2012;95(1-2):67-72. View abstract.

Grungreiff K, Albrecht M, and Strenge-Hesse A. Nut van medicinale levertherapie in de huisartsenpraktijk. Med Welt 1995;46:222-227.

Hasani-Ranjbar, S., Larijani, B., and Abdollahi, M. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm.Allergy Drug Targets. 2009;8(1):2-10. View abstract.

Hasani-Ranjbar, S., Nayebi, N., Moradi, L., Mehri, A., Larijani, B., and Abdollahi, M. The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review. Curr.Pharm.Des 2010;16(26):2935-2947. Bekijk abstract.

Hawke, R. L., Schrieber, S. J., Soule, T. A., Wen, Z., Smith, P. C., Reddy, K. R., Wahed, A. S., Belle, S. H., Afdhal, N. H., Navarro, V. J., Berman, J., Liu, Q. Y., Doo, E., and Fried, M. W. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J.Clin.Pharmacol. 2010;50(4):434-449. View abstract.

Hikino, H., Kiso, Y., Wagner, H., and Fiebig, M. Antihepatotoxische werking van flavonolignanen uit Silybum marianum vruchten. Planta Med 1984;50(3):248-250. View abstract.

Hussain, S. A. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J.Med.Food 2007;10(3):543-547. Bekijk abstract.

Iakimchuk, G. N. and Gendrikson, L. N. . Eksp.Klin.Gastroenterol. 2011;(7):64-69. View abstract.

Jacobs, B. P., Dennehy, C., Ramirez, G., Sapp, J., and Lawrence, V. A. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 10-15-2002;113(6):506-515. View abstract.

Katiyar, S. K., Korman, N. J., Mukhtar, H., and Agarwal, R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl.Cancer Inst. 4-16-1997;89(8):556-566. View abstract.

Kiesewetter, E., Leodolter, I., and Thaler, H. . Leber Magen Darm 1977;7(5):318-323. View abstract.

Kittur, S., Wilasrusmee, S., Pedersen, W. A., Mattson, M. P., Straube-West, K., Wilasrusmee, C., Lubelt, B., and Kittur, D. S. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. J Mol.Neurosci. 2002;18(3):265-269. View abstract.

Ladas, E. J., Kroll, D. J., Oberlies, N. H., Cheng, B., Ndao, D. H., Rheingold, S. R., and Kelly, K. M. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer 1-15-2010;116(2):506-513. View abstract.

Lahiri-Chatterjee, M., Katiyar, S. K., Mohan, R. R., and Agarwal, R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 2-1-1999;59(3):622-632. View abstract.

Lang, I., Deak, G., Nekam, K., Muzes, G., Gonzalez-Cabello, R., Gergely, P., and Feher, J. Hepatoprotective and immunomodulatory effects of antioxidant therapy. Acta Med Hung. 1988;45(3-4):287-295. View abstract.

Li, J., Lin, W. F., Pan, Y. Y., and Zhu, X. Y. . Zhonghua Gan Zang.Bing.Za Zhi. 2010;18(5):385-386. View abstract.

Lirussi F, Nassuato G, Orlando R, and et al. Treatment of active cirrhosis with ursodeoxycholic acid and a free radical scavenger: Een twee jaar durend prospectief onderzoek. Med Sci Ress 1995;23:31-33.

Locher, R., Suter, P. M., Weyhenmeyer, R., and Vetter, W. Inhibitory action of silibinin on low density lipoprotein oxidation. Arzneimittelforschung. 1998;48(3):236-239. View abstract.

Loguercio, C., Andreone, P., Brisc, C., Brisc, M. C., Bugianesi, E., Chiaramonte, M., Cursaro, C., Danila, M., de, Sio, I, Floreani, A., Freni, M.A., Grieco, A., Groppo, M., Lazzari, R., Lobello, S., Lorefice, E., Margotti, M., Miele, L., Milani, S., Okolicsanyi, L., Palasciano, G., Portincasa, P., Saltarelli, P., Smedile, A., Somalvico, F., Spadaro, A., Sporea, I., Sorrentino, P., Vecchione, R., Tuccillo, C., Del Vecchio, Blanco C., and Federico, A. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic.Biol.Med. 5-1-2012;52(9):1658-1665. Bekijk abstract.

Lucena, M. I., Andrade, R. J., de la Cruz, J. P., Rodriguez-Mendizabal, M., Blanco, E., and Sanchez, de la Cuesta. Effecten van silymarine MZ-80 op oxidatieve stress bij patiënten met alcoholische cirrose. Resultaten van een gerandomiseerde, dubbelblinde, placebogecontroleerde klinische studie. Int J Clin Pharmacol Ther 2002;40(1):2-8. View abstract.

Magdalan, J., Piotrowska, A., Gomulkiewicz, A., Sozanski, T., Szelag, A., and Dziegiel, P. Influence of commonly used clinical antidotes on antioxidant systems in human hepatocyte culture intoxicated with alpha-amanitin. Hum.Exp.Toxicol. 2011;30(1):38-43. Bekijk abstract.

Magliulo, E., Gagliardi, B., and Fiori, G. P. . Med Klin. 7-14-1978;73(28-29):1060-1065. View abstract.

Marcelli R, Bizzoni P, Conte D, and et al. Randomized controlled study of the efficacy and tolerability of a short course of IdB 1016 in the treatment of chronic persistent hepatitis. Eur Bull Drug Res 1992;1(3):131-135.

Marena C en Lampertico M. Preliminary clinical development of silipide: a new complex of silybin in toxic liver disorders. Planta Med 1991;57(2):A124-A125.

Mereish, K. A., Bunner, D. L., Ragland, D. R., and Creasia, D. A. Protection against microcystin-LR-induced hepatotoxicity by Silymarin: biochemistry, histopathology, and lethality. Pharm.Res 1991;8(2):273-277. View abstract.

Mira ML, Azevedo MS, and Manso C. The neutralization of hydroxyl radical by silibin, sorbinil and bendazac. Free Radical Res Commun 1987;4(125):129.

Mironets VI, Krasovskaia EA, and Polishchuk II. . Vrach Delo 1990;7:86-87.

Moosavifar, N., Mohammadpour, A. H., Jallali, M., Karimiz, G., and Saberi, H. Evaluation of effect of silymarin on granulosa cell apoptosis and follicular development in patients undergoing in vitro fertilization. East Mediterr.Health J. 2010;16(6):642-645. View abstract.

Nassuato, G., Iemmolo, R. M., Strazzabosco, M., Lirussi, F., Deana, R., Francesconi, M. A., Muraca, M., Passera, D., Fragasso, A., Orlando, R., and . Effect van Silibinin op de biliaire lipidensamenstelling. Experimentele en klinische studie. J Hepatol. 1991;12(3):290-295. View abstract.

Pade, D. and Stavchansky, S. Selection of bioavailability markers for herbal extracts based on in silico descriptors and their correlation to in vitro permeability. Mol.Pharm. 2008;5(4):665-671. View abstract.

Palasciano G, Portincasa P, Palmieri V, and et al. The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs. Current Therapeutic Research 1994;55(5):537-545.

Par, A., Roth, E., Miseta, A., Hegedus, G., Par, G., Hunyady, B., and Vincze, A. . Orv.Hetil. 1-11-2009;150(2):73-79. View abstract.

Payer, B. A., Reiberger, T., Rutter, K., Beinhardt, S., Staettermayer, A. F., Peck-Radosavljevic, M., and Ferenci, P. Succesvolle HCV-eradicatie en remming van HIV-replicatie door intraveneuze silibinine in een HIV-HCV-gecoïnfecteerde patiënt. J.Clin.Virol. 2010;49(2):131-133. View abstract.

Rambaldi, A., Jacobs, B. P., and Gluud, C. Mariadistel voor leveraandoeningen door alcohol en/of het hepatitis B- of C-virus. Cochrane.Database.Syst.Rev 2007;(4):CD003620. View abstract.

Ramellini, G. and Meldolesi, J. Leverbescherming door silymarine: in vitro effect op gedissocieerde hepatocyten van ratten. Arzneimittelforschung. 1976;26(1):69-73. View abstract.

Ramirez-Santos, A., Perez-Bustillo, A., Gonzalez-Sixto, B., Suarez-Amor, O., and Rodriguez-Prieto, M. A. . Actas Dermosifiliogr. 2011;102(9):744-745. Bekijk abstract.

Reutter, F. W. and Haase, W. . Schweiz Rundsch.Med Prax. 9-9-1975;64(36):1145-1151. View abstract.

Savio, D., Harrasser, P. C., and Basso, G. Softgel capsule technology as an enhancer device for the absorption of natural principles in humans. Een cross-over gerandomiseerde studie naar de biologische beschikbaarheid van silybine. Arzneimittelforschung. 1998;48(11):1104-1106. View abstract.

Sayyah, M., Boostani, H., Pakseresht, S., and Malayeri, A. Vergelijking van Silybum marianum (L.) Gaertn. met fluoxetine bij de behandeling van Obsessief-Compulsieve Stoornis. Prog.Neuropsychopharmacol.Biol.Psychiatry 3-17-2010;34(2):362-365. Bekijk abstract.

Schrieber, S. J., Hawke, R. L., Wen, Z., Smith, P. C., Reddy, K. R., Wahed, A. S., Belle, S. H., Afdhal, N. H., Navarro, V. J., Meyers, C. M., Doo, E., and Fried, M. W. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos. 2011;39(12):2182-2190. View abstract.

Schrieber, S. J., Wen, Z., Vourvahis, M., Smith, P. C., Fried, M. W., Kashuba, A. D., and Hawke, R. L. The pharmacokinetics of silymarin is changed in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 2008;36(9):1909-1916. Bekijk abstract.

Schriewer, H. en Rauen, H. M. . Arzneimittelforschung. 1977;27(9):1691-1694. View abstract.

Schriewer, F. H., Roobol, M. J., Boeve, E. R., de Mutsert, R., Zuijdgeest-van Leeuwen, S. D., Kersten, I., Wildhagen, M. F., and van Helvoort, A. Randomized, double-blind, placebo-controlled cross-over study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 2005;48(6):922-930. View abstract.

Schuppan D, Strosser W, Burkard G, and et al. Invloed van Legalon(TM) 140 op het metabolisme van collageen bij patiënten met een chronische leveraandoening–Beoordeling door meting van PIIINP-waarden. Zeitschrift fur Allgemeinmedizin 1998;74:577-584.

Skottova, N. and Krecman, V. Silymarin as a potential hypocholesterolaemic drug. Physiol Res 1998;47(1):1-7. View abstract.

Somogyi, A., Ecsedi, G. G., Blazovics, A., Miskolczi, K., Gergely, P., and Feher, J. Short term treatment of type II hyperlipoproteinaemia with silymarin. Acta Med Hung. 1989;46(4):289-295. View abstract.

Sonnenbichler J and Zetl I. Stimulating influence of a flavonolignane derivative on proliferation, RNA synthesis and protein synthesis in liver cells. In: Okoliczanyi L, Csomos G, Crepaldi G, and et al. Assessment and Management of Hepatobiliary Disease. Berlijn: Springer-Verlag;1987.

Sonnenbichler, J. and Zetl, I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog.Clin Biol Res 1986;213:319-331. View abstract.

Sonnenbichler, J., Goldberg, M., Hane, L., Madubunyi, I., Vogl, S., and Zetl, I. Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-respons in hepatoma and other malign cell lines. Biochem.Pharmacol 2-1-1986;35(3):538-541. View abstract.

Soto, C. P., Perez, B. L., Favari, L. P., and Reyes, J. L. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C.Pharmacol Toxicol.Endocrinol. 1998;119(2):125-129. View abstract.

Studlar M. Die Behandlung chronischer Leberkrankungen mit Silymarin und B-Vitaminen. Therapiewoche 1985;35:3375-3378.

Tiwari, P., Kumar, A., Balakrishnan, S., Kushwaha, H. S., and Mishra, K. P. Silibinin-induced apoptosis in MCF7 and T47D human breast carcinoma cells involves caspase-8 activation and mitochondrial pathway. Cancer Invest 2011;29(1):12-20. View abstract.

Tyutyulkova, N., Tuneva, S., Gorantcheva, U., Tanev, G., Zhivkov, V., Chelibonova-Lorer, H., and Bozhkov, S. Hepatoprotectief effect van silymarine (carsil) op de lever van met D- galactosamine behandelde ratten. Biochemisch en morfologisch onderzoek. Methods Find.Exp Clin Pharmacol 1981;3(2):71-77. Bekijk abstract.

Unger, M. . Wien.Med.Wochenschr. 2010;160(21-22):571-577. View abstract.

Vailati A, Aristia L, Sozze E, and et al. Gerandomiseerd open onderzoek naar de dosis-effect relatie van een korte kuur IdB 1016 bij patiënten met virale of alcoholische hepatitis. Fitoterapia 1993;64(3):219-228.

Valenzuela, A., Lagos, C., Schmidt, K., and Videla, L. A. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem.Pharmacol 6-15-1985;34(12):2209-2212. View abstract.

Velussi M, Cernigoi AM, Viezzoli L, and et al. Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Curr Ther Res 1993;53(5):533-545.

Vidlar, A., Vostalova, J., Ulrichova, J., Student, V., Krajicek, M., Vrbkova, J., and Simanek, V. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy – a six month placebo-controlled double-blind clinical trial. Biomed.Pap.Med.Fac.Univ Palacky.Olomouc.Czech.Repub. 2010;154(3):239-244. View abstract.

Wagoner, J., Morishima, C., Graf, T. N., Oberlies, N. H., Teissier, E., Pecheur, E. I., Tavis, J. E., and Polyak, S. J. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS.One. 2011;6(1):e16464. View abstract.

Wallace, S., Vaughn, K., Stewart, B. W., Viswanathan, T., Clausen, E., Nagarajan, S., and Carrier, D. J. Milk thistle extracts inhibit the oxidation of low-density lipoprotein (LDL) and subsequent scavenger receptor-dependent monocyte adhesion. J Agric Food Chem 6-11-2008;56(11):3966-3972. View abstract.

Wenzel, S., Stolte, H., and Soose, M. Effects of silibinin and antioxidants on high glucose-induced alterations of fibronectin turnover in human mesangial cell cultures. J Pharmacol Exp Ther 1996;279(3):1520-1526. View abstract.

Weyhenmeyer, R., Mascher, H., and Birkmayer, J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int.J Clin Pharmacol Ther Toxicol 1992;30(4):134-138. View abstract.

Yakoot, M. and Salem, A. Spirulina platensis versus silymarine in de behandeling van chronische hepatitis C virus infectie. Een pilot gerandomiseerde, vergelijkende klinische studie. BMC.Gastroenterol. 2012;12:32. Bekijk abstract.

Zhang, J. Q., Mao, X. M., and Zhou, Y. P. . Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 1993;13(12):725-6, 708. View abstract.

Zhang, J., Luan, Q., Liu, Y., Lee, D. Y., and Wang, Z. A comparison of the diastereoisomers, silybin A and silybin B, on the induction of apoptosis in K562 cells. Nat.Prod.Commun. 2011;6(11):1653-1656. View abstract.

Zi, X., Mukhtar, H., and Agarwal, R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem.Biophys.Res Commun. 10-9-1997;239(1):334-339. View abstract.

Zima, T., Kamenikova, L., Janebova, M., Buchar, E., Crkovska, J., and Tesar, V. The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail. 1998;20(3):471-479. View abstract.

Zou, C. G., Agar, N. S., and Jones, G. L. Oxidative insult to human red blood cells induced by free radical initiator AAPH and its inhibition by a commercial antioxidant mixture. Life Sci 5-25-2001;69(1):75-86. View abstract.

Abenavoli L, Capasso R, Milic N, Capasso F. Mariadistel in leverziekten: verleden, heden, toekomst. Phytother Res 2010;24:1423-32. Bekijk abstract.

Adverse Drug Reactions Advisory Committee. An adverse reaction to the herbal medication milk thistle (Silybum marianum). Med J Aust 1999;170:218-9. Bekijk abstract.

Anon. Mariadistel: Effecten op leverziekte en levercirrose en klinische bijwerkingen. Samenvatting, Evidence Report/Technology Assessment: Nummer 21, September 2000. Agency for Healthcare Research and Quality, Rockville, MD. Beschikbaar op: http://www.ahrq.gov/clinic/epcsums/milktsum.htm

Bakhshaee M, Jabbari F, Hoseini S, et al. Effect van silymarine bij de behandeling van allergische rhinitis. Otolaryngology – Head and Neck Surgery 2011;145:904-9. View abstract.

Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Farmacol Toxicol 2000;86:250-6. View abstract.

Boerth J, Strong KM. The clinical utility of milk thistle (Silybum marianum) in cirrhosis of the liver. J Herb Pharmacother 2002;2:11-7. View abstract.

Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Fytomedicine 2000;7:273-82. View abstract.

Budzinski JW, Trudeau VL, Drouin CE, et al. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol 2007;85:966-78. Bekijk abstract.

Bunout D, Hirsch S, Petermann M. Rev Med Chil 1992;120:1370-5. View abstract.

Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 1993;31:456-60. View abstract.

Chevallier A. Encyclopedia of Herbal Medicine. 2nd ed. New York, NY: DK Publ, Inc., 2000.

Deng JW, Shon JH, Shin HJ, et al. Effect van silymarine supplement op de farmacokinetiek van rosuvastatine. Pharm Res 2008;25:1807-14. View abstract.

DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003;23:866-70.. View abstract.

Doehmer J, Weiss G, McGregor GP, Appel K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro 2011;25:21-7. View abstract.

Eagon PK, Elm MS, Hunter DS, et al. Geneeskrachtige kruiden: modulatie van oestrogeenwerking. Era of Hope Mtg, Dept Defense; Breast Cancer Res Prog, Atlanta, GA 2000;Jun 8-11.

El-Shitany NA, Hegazy S, El-Desoky K. Evidences for antiosteoporotic and selective oestrogeen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats. Fytomedicine. 2010;17(2):116-25. View abstract.

FDA brief aan GCI Nutrients Worldwide Inc. 16 februari 2005. Beschikbaar op: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/CyberLetters/ucm126468.pdf (Accessed 4/2/15).

Feher J, Deak G, Muzes G, et al. . Orv Hetil 1989;130:2723-7. View abstract.

Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105-13. View abstract.

Flora K, Hahn M, Rosen H, Benner K. Mariadistel (Silybum marianum) voor de therapie van leverziekten. Am J Gastroenterol 1998;93:139-43. Bekijk abstract.

Foster S, Tyler VE. Tyler’s Honest Herbal, 4th ed., Binghamton, NY: Haworth Herbal Press, 1999.

Freedman ND, Curto TM, Morishima C, et al. Silymarine gebruik en leverziekteprogressie in de hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial. Aliment Pharmacol Ther 2011;33:127-37. View abstract.

Gufford BT, Chen G, Vergara AG, et al. Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction. Drug Metab Dispos. 2015;43(9):1353-9. View abstract.

Gurley B, Hubbard MA, Williams DK, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 2006;46:201-13. View abstract.

Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, mariadistel, en zaagpalm. Clin Pharmacol Ther 2004;76:428-40. . View abstract.

Holtmann G, Madisch A, Juergen H, et al. A double-blind, randomized, placebo-controlled trial on the effects of an herbal preparation in patients with functional dyspepsia . Ann Mtg Digestive Disease Week 1999 May.

Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 1983;2:183-95. View abstract.

Huseini HF, Larijani B, Heshmat R, et al. De werkzaamheid van Silybum marianum (L.) Gaertn. (silymarine) bij de behandeling van type II diabetes: een gerandomiseerde, dubbelblinde, placebogecontroleerde, klinische studie. Phytother Res 2006;20;1036-9. View abstract.

Jalloh MA, Gregory PJ, Hein D, et al. Dietary supplement interactions with antiretrovirals: een systematisch overzicht. Int J STD AIDS. 2017 Jan;28(1):4-15. Bekijk abstract.

Jiao Z, Shi XJ, Li ZD, et al. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. Br.J.Clin.Pharmacol. 2009;68(1):47-60. View abstract.

Kim CS, Choi SJ, Park CY, et al. Effecten van silybinine op de farmacokinetiek van tamoxifen en zijn actieve metaboliet, 4-hydroxytamoxifen bij ratten. Anticancer Res 2010;30:79-85. View abstract.

Kim DH, Jin YH, Park JB, Kobashi K. Silymarin and its components are inhibitors of beta-glucuronidase. Biol Pharm Bull 1994;17:443-5. View abstract.

Lee JI, Narayan M, Barrett JS. Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007;845(1):95-103. View abstract.

Madisch A, Holtmann G, Mayr G, et al. Behandeling van functionele dyspepsie met een kruidenpreparaat. Een dubbelblind, gerandomiseerd, placebogecontroleerd, multicenter onderzoek. Spijsvertering 2004;69:45-52. Bekijk abstract.

Madisch A, Melderis H, Mayr G, et al. . Z Gastroenterol 2001;39(7):511-7. View abstract.

Maitrejean M, Comte G, Barron D, et al. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett 2000;10:157-60. View abstract.

Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 1999;163:6800-9. View abstract.

Melzer J, Rosch W, Reichling J, et al. Meta-analyse: fytotherapie van functionele dyspepsie met het kruidengeneesmiddelenpreparaat STW 5 (Iberogast). Aliment Pharmacol Ther 2004;20:1279-87. View abstract.

Moayedi B, Gharagozloo M, Esmaeil N, et al. A randomized double-blind, placebo-controlled study of therapeutic effects of silymar in β-thalassemia major patients receiving desferrioxamine. Eur J Haematol 2013;90(3):202-9. View abstract.

Pares A, Planas R, Torres M, et al. Effecten van silymarine bij alcoholische patiënten met levercirrose: resultaten van een gecontroleerde, dubbelblinde, gerandomiseerde en multicenter trial. J Hepatol 1998;28:615-21. View abstract.

Piscitelli SC, Formentini E, Burstein AH, et al. Effect van mariadistel op de farmacokinetiek van indinavir bij gezonde vrijwilligers. Farmacotherapie 2002;22:551-6. View abstract.

Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007;23:117-22. View abstract.

Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementarmed 2008;15:9-20. View abstract.

Salmi HA, Sarna S. Effect van silymarine op chemische, functionele en morfologische veranderingen van de lever. Een dubbelblind, gecontroleerd onderzoek. Scand J Gastroenterol 1982;17:517-21. View abstract.

Seidlová-Wuttke D, Becker T, Christoffel V, Jarry H, Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J Steroid Biochem Mol Biol. 2003;86(2):179-88. View abstract.

Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. Stimulerende effecten van silibinin en silicristin uit de mariadistel Silybum marianum op niercellen. J Pharmacol Exp Ther 1999;290:1375-83. View abstract.

Sridar C, Goosen TC, Kent UM, et al. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004;32:587-94. View abstract.

Suksomboon N, Poolsup N, Boonkaew S, Suthisisang CC. Meta-analyse van het effect van kruidensupplementen op de glycemische controle bij diabetes type 2. J Ethnopharmacol 2011;137(3):1328-1333. View abstract.

Szilard S, Szentgyorgyi D, Demeter I. Beschermend effect van Legalon bij werknemers blootgesteld aan organische oplosmiddelen. Acta Med Hung 1988;45:249-56. View abstract.

Tanamly MD, Tadros F, Labeeb S, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis 2004;36:752-9. Bekijk abstract.

Trinchet JC, Coste T, Levy VG. . Gastroenterol Clin Biol 1989;13:120-4. View abstract.

van Erp NP, Baker SD, Zhao M, et al. Effect van mariadistel (Silybum marianum) op de farmacokinetiek van irinotecan. Clin Cancer Res 2005;11:7800-6. View abstract.

Velussi M, Cernigoi AM, De Monte A, et al. Langdurige (12 maanden) behandeling met een antioxidant geneesmiddel (silymarine) is effectief op hyperinsulinemie, exogene behoefte aan insuline en malondialdehyde niveaus bij cirrotische diabetespatiënten. J Hepatol 1997;26:871-9. View abstract.

Venkataramanan R, Ramachandran V, Komoroski BJ, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000;28:1270-3. View abstract.

Vostalova J, Vidlar A, Ulrichova J, et al. Gebruik van selenium-silymarinemix vermindert symptomen van de lagere urinewegen en prostaatspecifiek antigeen bij mannen. Fytomedicine 2013;21:75-81. View abstract.

Yang Z, Zhuang L, Lu Y, Xu Q, Chen X. Effecten en tolerantie van silymarine (mariadistel) bij patiënten met chronische hepatitis C-virusinfectie: een meta-analyse van gerandomiseerde gecontroleerde trials. Biomed Res Int. 2014;941085. doi: 10.1155/2014/941085. Epub 2014 Aug 27. View abstract.

Zhu W, Zhang JS, Young CY. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 2001;22:1399-403. View abstract.